

# Ute M Moll

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8095081/publications.pdf>

Version: 2024-02-01

40  
papers

8,320  
citations

172457

29  
h-index

289244

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

13843  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 642603.	2.8	25
2	Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins. <i>Cell Death and Disease</i> , 2020, 11, 274.	6.3	12
3	Tissue-specific roles of p73 in development and homeostasis. <i>Journal of Cell Science</i> , 2019, 132, .	2.0	29
4	Cajal-Retzius neurons are required for the development of the human hippocampal fissure. <i>Journal of Anatomy</i> , 2019, 235, 569-589.	1.5	16
5	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	11.2	4,036
6	Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism. <i>Cell Death and Differentiation</i> , 2018, 25, 144-153.	11.2	63
7	Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target. <i>Cancers</i> , 2018, 10, 188.	3.7	84
8	Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. <i>Cancer Cell</i> , 2018, 34, 298-314.e7.	16.8	162
9	p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. <i>Cell Death and Disease</i> , 2017, 8, e2661-e2661.	6.3	75
10	Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. <i>Cancer Research</i> , 2017, 77, 1250-1260.	0.9	68
11	Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner. <i>Cell Death and Disease</i> , 2017, 8, e2683-e2683.	6.3	13
12	Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy. <i>Cell Death and Differentiation</i> , 2017, 24, 3-5.	11.2	27
13	Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin. <i>FASEB Journal</i> , 2017, 31, 526-543.	0.5	21
14	A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems. <i>Journal of Molecular Biology</i> , 2016, 428, 4154-4167.	4.2	45
15	TAp73 is a central transcriptional regulator of airway multiciliogenesis. <i>Genes and Development</i> , 2016, 30, 1300-1312.	5.9	112
16	MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. <i>Molecular Cell</i> , 2016, 61, 68-83.	9.7	82
17	MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. <i>Molecular Cell</i> , 2015, 59, 243-257.	9.7	70
18	p53 <sup>Δ</sup> is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3287-96.	7.1	73

#	ARTICLE	IF	CITATIONS
19	Targeting tumour-supportive cellular machineries in anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 179-196.	46.4	202
20	Cortical hypoplasia and ventriculomegaly of p73-deficient mice: Developmental and adult analysis. <i>Journal of Comparative Neurology</i> , 2014, 522, 2663-2679.	1.6	20
21	TAp73 is essential for germ cell adhesion and maturation in testis. <i>Journal of Cell Biology</i> , 2014, 204, 1173-1190.	5.2	46
22	Mitochondrial p53 mediates a transcription-independent regulation of cell respiration and interacts with the mitochondrial F <sub>1</sub> F <sub>0</sub> -ATP synthase. <i>Cell Cycle</i> , 2013, 12, 2781-2793.	2.6	59
23	Role of p53 family members p73 and p63 in human hematological malignancies. <i>Leukemia and Lymphoma</i> , 2012, 53, 2116-2129.	1.3	40
24	Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells. <i>Molecular Cancer Research</i> , 2011, 9, 577-588.	3.4	238
25	Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3624-3629.	7.1	85
26	Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2070-2080.	8.2	39
27	p73 Suppresses Polyploidy and Aneuploidy in the Absence of Functional p53. <i>Molecular Cell</i> , 2007, 27, 647-659.	9.7	75
28	Transcription-independent pro-apoptotic functions of p53. <i>Current Opinion in Cell Biology</i> , 2005, 17, 631-636.	5.4	430
29	p63 and p73: roles in development and tumor formation. <i>Molecular Cancer Research</i> , 2004, 2, 371-86.	3.4	200
30	p63 and p73: Roles in Development and Tumor Formation. <i>Molecular Cancer Research</i> , 2004, 2, 371-386.	3.4	401
31	<i>The Role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness.</i> Commentary re: F. Koga et al., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. <i>Clin. Cancer Res.</i> , 9: 5501-5507, 2003, and P. Puig et al., p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder Cancer. <i>Clin. Cancer Res.</i> , 9: 5642-5651, 2003. <i>Clinical Cancer Research</i> , 2003, 9, 5437-41.	7.0	22
32	The MDM2-p53 interaction. <i>Molecular Cancer Research</i> , 2003, 1, 1001-8.	3.4	621
33	ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors. <i>Journal of Experimental Medicine</i> , 2002, 196, 765-780.	8.5	309
34	Hypoxia death stimulus induces translocation of p53 protein to mitochondria. <i>FEBS Letters</i> , 2001, 488, 110-115.	2.8	153
35	Nuclear and mitochondrial apoptotic pathways of p53. <i>FEBS Letters</i> , 2001, 493, 65-69.	2.8	195
36	Corrigendum to: Hypoxia death stimulus induces translocation of p53 protein to mitochondria. <i>FEBS Letters</i> , 2001, 501, 97-98.	2.8	2

#	ARTICLE	IF	CITATIONS
37	Disrupting the p53-mdm2 interaction as a potential therapeutic modality. Drug Resistance Updates, 2000, 3, 217-221.	14.4	11
38	DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene, 1999, 18, 3114-3126.	5.9	79
39	Functional histology of the neuroendocrine thymus. Microscopy Research and Technique, 1997, 38, 300-310.	2.2	32
40	Extraction of type-IV collagenase/gelatinase from plasma membranes of human cancer cells. International Journal of Cancer, 1990, 45, 1137-1142.	5.1	48